- Home
- NIO vs ROIV Comparison
NIO vs ROIV Comparison
Compare NIO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIO | ROIV |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | NIO | ROIV |
|---|---|---|
| Price | $5.14 | $21.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $6.73 | ★ $24.31 |
| AVG Volume (30 Days) | ★ 41.2M | 8.2M |
| Earning Date | 11-25-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,189,444,895.00 | $20,329,000.00 |
| Revenue This Year | $33.27 | N/A |
| Revenue Next Year | $50.24 | $741.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.90 | N/A |
| 52 Week Low | $3.02 | $8.73 |
| 52 Week High | $8.02 | $23.47 |
Technical Indicators
Market Signals| Indicator | NIO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 53.08 |
| Support Level | $4.86 | $21.36 |
| Resistance Level | $5.79 | $22.72 |
| Average True Range (ATR) | 0.18 | 0.80 |
| MACD | 0.09 | -0.13 |
| Stochastic Oscillator | 24.32 | 45.71 |
Price Performance
Historical ComparisonAbout NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.